AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $254,652,008 | -3.0% | 20,941,777 | +0.2% | 0.01% | 0.0% |
| Q2 2023 | $262,486,329 | +19.9% | 20,898,593 | +5.9% | 0.01% | +16.7% |
| Q1 2023 | $218,894,699 | -11.0% | 19,738,025 | -2.0% | 0.01% | -25.0% |
| Q4 2022 | $245,885,933 | +18.4% | 20,138,078 | +1.2% | 0.01% | +14.3% |
| Q3 2022 | $207,741,000 | -4.5% | 19,898,552 | -1.7% | 0.01% | 0.0% |
| Q2 2022 | $217,484,000 | +17.2% | 20,249,858 | +3.4% | 0.01% | +40.0% |
| Q1 2022 | $185,546,000 | -18.9% | 19,593,001 | -1.1% | 0.01% | -16.7% |
| Q4 2021 | $228,810,000 | +22.3% | 19,810,348 | +1.1% | 0.01% | +20.0% |
| Q3 2021 | $187,047,000 | -4.4% | 19,586,198 | -3.5% | 0.01% | 0.0% |
| Q2 2021 | $195,714,000 | -8.0% | 20,302,270 | -5.7% | 0.01% | -16.7% |
| Q1 2021 | $212,636,000 | -57.9% | 21,521,879 | -1.6% | 0.01% | -62.5% |
| Q4 2020 | $505,149,000 | +70.6% | 21,877,442 | +4.3% | 0.02% | +45.5% |
| Q3 2020 | $296,079,000 | -11.8% | 20,968,808 | -5.8% | 0.01% | -15.4% |
| Q2 2020 | $335,618,000 | +71.0% | 22,255,818 | +4.8% | 0.01% | +30.0% |
| Q1 2020 | $196,248,000 | -3.4% | 21,239,016 | +1.8% | 0.01% | +25.0% |
| Q4 2019 | $203,140,000 | +22.2% | 20,856,107 | +0.6% | 0.01% | +14.3% |
| Q3 2019 | $166,242,000 | -28.3% | 20,728,245 | +11.6% | 0.01% | -30.0% |
| Q2 2019 | $231,885,000 | +1.6% | 18,580,413 | +10.8% | 0.01% | 0.0% |
| Q1 2019 | $228,136,000 | +44.1% | 16,774,752 | +1.5% | 0.01% | +25.0% |
| Q4 2018 | $158,279,000 | -20.0% | 16,521,820 | +0.9% | 0.01% | -11.1% |
| Q3 2018 | $197,967,000 | -20.9% | 16,374,336 | +2.2% | 0.01% | -25.0% |
| Q2 2018 | $250,190,000 | +10.2% | 16,017,301 | +6.1% | 0.01% | +9.1% |
| Q1 2018 | $226,957,000 | +15.0% | 15,090,252 | +10.1% | 0.01% | +22.2% |
| Q4 2017 | $197,317,000 | -2.1% | 13,712,097 | +2.6% | 0.01% | -10.0% |
| Q3 2017 | $201,608,000 | +69.9% | 13,369,236 | +13.5% | 0.01% | +66.7% |
| Q2 2017 | $118,646,000 | +39.0% | 11,781,958 | -1.6% | 0.01% | +20.0% |
| Q1 2017 | $85,330,000 | +144527.1% | 11,967,596 | +101011.8% | 0.01% | – |
| Q4 2016 | $59,000 | -70.1% | 11,836 | -55.6% | 0.00% | – |
| Q3 2016 | $197,000 | +36.8% | 26,648 | +0.8% | 0.00% | – |
| Q2 2016 | $144,000 | +108.7% | 26,443 | +224.8% | 0.00% | – |
| Q1 2016 | $69,000 | +86.5% | 8,142 | +115.3% | 0.00% | – |
| Q4 2015 | $37,000 | -9.8% | 3,782 | +28.7% | 0.00% | – |
| Q3 2015 | $41,000 | 0.0% | 2,939 | 0.0% | 0.00% | – |
| Q2 2015 | $41,000 | – | 2,939 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |